Document Detail


Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
MedLine Citation:
PMID:  17541498     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of our study was to investigate determinants of bone mineral density (BMD) measured by dual X-ray absorptiometry at the lumbar spine (BMD-LS) and at the femoral neck (BMD-FN) in patients with rheumatoid arthritis (RA) with special respect to bone resorbing proinflammatory cytokines and their physiological antagonists. In 142 RA patients the following parameters were measured in parallel with BMD: serum levels of soluble receptor activator of nuclear factor kappa-B-ligand (sRANKL), osteoprotegerin (OPG), interleukin (IL)-6, soluble glycoprotein 130 (sgp130), 25-hydroxyvitamin D3 (25OHD(3)), 1,25-dihydroxyvitamin D3 (1,25[OH](2)D(3)), intact parathyroid hormone, osteocalcin, ionized calcium, renal excretion of pyridinolin and deoxypyridinolin, C-reactive protein, and erythrocyte sedimentation rate (ESR). No significant differences of sRANKL, OPG, IL-6, and spg130 were found between patients with osteoporosis (47.9% of patients), osteopenia (36.6%), and normal BMD (15.5%). However, total sRANKL was significantly higher in postmenopausal women with osteoporosis at FN than in those without (p < 0.05) and showed a negative correlation with BMD-LS in patients older than 60 years (p = 0.01). BMD-LS and BMD-FN (p < 0.001) and total sRANKL (p < 0.01) were negatively related with the age of the patients. Only IL-6 (positive correlation, p < 0.001) and 1,25(OH)(2)D(3) (negative correlation, p < 0.001) but not sRANKL, OPG, and sgp130 were related to disease activity. Using multiple linear regression analysis, menopause was identified as the crucial negative determinant of BMD-LS (R (2) = 0.94, p = 0.001), whereas cumulative glucocorticoid dose (beta = -0.80, p = 0.001) and ESR (beta = -0.44, p = 0.016) were the negative determinants of BMD-FN (R (2) = 0.86, p = 0.001). The results indicate that influences of age and gender must be considered in investigations on the relationship between BMD and sRANKL in RA and that high serum levels of sRANKL seems to be associated with osteoporosis only in subgroups of RA patients.
Authors:
P Oelzner; S Franke; G Lehmann; T Eidner; A Müller; G Wolf; G Hein
Related Documents :
15968288 - Bone mineral density in children with thalassaemia major: determining factors and effec...
10714088 - The influence of gastrectomy on the change of bone metabolism and bone density.
6836748 - Bone marrow involvement at onset of hodgkin's disease.
9042988 - Long-term effect of gluten restriction on bone mineral density of patients with coeliac...
12787798 - Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis c: a pilo...
23199208 - Exocrine pancreatic insufficiency following esophagectomy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-05-31
Journal Detail:
Title:  Clinical rheumatology     Volume:  26     ISSN:  0770-3198     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-09     Completed Date:  2008-02-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  2127-35     Citation Subset:  IM    
Affiliation:
Division of Rheumatology and Osteology, Department of Internal Medicine III, Friedrich Schiller University, Jena, Germany. peter.oelzner@med.uni-jena.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Adolescent
Adult
Aged
Aged, 80 and over
Arthritis, Rheumatoid / blood*,  complications,  radiography
Biological Markers / blood
Bone Density / physiology*
Bone Resorption / blood,  complications,  epidemiology
Disease Progression
Female
Humans
Incidence
Male
Middle Aged
Osteoprotegerin / metabolism*
Prognosis
RANK Ligand / metabolism*
Severity of Illness Index
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Osteoprotegerin; 0/RANK Ligand

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of complementary and alternative medicine by rheumatoid arthritis patients in Korea.
Next Document:  Neurogenic osteoarthropathy in leprosy.